<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
GTHX
G1 Therapeutics
$
()


  • G1 Therapeutics sees FY24 COSELA revenue $60M-$70M

    2/28/2024 - 06:37am
  • G1 Therapeutics reports Q4 EPS (21c), consensus (27c)

    2/28/2024 - 06:36am
  • Biotech Alert: Searches spiking for these stocks today

    2/16/2024 - 11:22am
  • Biotech Alert: Searches spiking for these stocks today

    2/15/2024 - 11:05am
  • G1 Therapeutics price target lowered by $2 at Needham, here's why

    2/13/2024 - 07:48am
  • G1 Therapeutics tumbles after DMC recommends Phase 3 trial continues

    2/13/2024 - 07:33am
  • G1 Therapeutics presents post hoc analyses on trilaciclib with chemotherapy

    12/5/2023 - 09:31am
  • G1 Therapeutics price target lowered to $9 from $11 at H.C. Wainwright

    11/2/2023 - 06:05am
  • G1 Therapeutics sees FY23 COSELA net revenue $44M-$47M

    11/1/2023 - 06:36am
  • G1 Therapeutics reports Q3 EPS (35c), consensus (33c)

    11/1/2023 - 06:34am
  • G1 Therapeutics announces four posers on real-world evidence on trilaciclib

    10/27/2023 - 07:12am
  • G1 Therapeutics' COSELA recommended in updated SCLC guidelines

    10/18/2023 - 08:03am
  • G1 Therapeutics downgraded to Underweight from Neutral at JPMorgan

    10/6/2023 - 05:20am
  • Biotech Alert: Searches spiking for these stocks today

    8/4/2023 - 11:10am
  • G1 Therapeutics reaffirms FY23 COSELA net revenue view $50M-$60M

    8/2/2023 - 06:46am
dynamic_feed Breaking News